1
|
Major A, Palese M, Ermis E, James A, Villarroel M, Klussmann FA, Hessissen L, Geel J, Khan MS, Dalvi R, Sullivan M, Kearns P, Frazier AL, Pritchard-Jones K, Nakagawara A, Rodriguez-Galindo C, Volchenboum SL. Mapping Pediatric Oncology Clinical Trial Collaborative Groups on the Global Stage. JCO Glob Oncol 2022; 8:e2100266. [PMID: 35157510 PMCID: PMC8853619 DOI: 10.1200/go.21.00266] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The global pediatric oncology clinical research landscape, particularly in Central and South America, Africa, and Asia, which bear the highest burden of global childhood cancer cases, is less characterized in the literature. Review of how existing pediatric cancer clinical trial groups internationally have been formed and how their research goals have been pursued is critical for building global collaborative research and data-sharing efforts, in line with the WHO Global Initiative for Childhood Cancer. Local stakeholder engagement is necessary to collaborate with global pediatric cancer trial groups.![]()
Collapse
Affiliation(s)
- Ajay Major
- Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
| | - Monica Palese
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Ebru Ermis
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Anthony James
- Department of Pediatrics, University of Chicago, Chicago, IL
| | - Milena Villarroel
- Grupo de América Latina de Oncología Pediátrica (GALOP), Hospital Luis Calvo Mackenna, National Pediatric Cancer Program (PINDA), Santiago, Chile
| | - Federico Antillon Klussmann
- National Unit of Pediatric Oncology, Francisco Marroquin University School of Medicine, Guatemala City, Guatemala
| | - Laila Hessissen
- Pediatric Hematology and Oncology, Mohammed V University of Rabat, Rabat, Morocco
| | - Jennifer Geel
- Faculty of Health Sciences, Division of Pediatric Haematology and Oncology, Department of Pediatrics and Child Health, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
| | - Muhammad Saghir Khan
- Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Al Madinah, Saudi Arabia
| | - Rashmi Dalvi
- Bombay Hospital Institute of Medical Sciences and SRCC Children's Hospital, Mumbai, India
| | - Michael Sullivan
- Children's Cancer Centre, Royal Children's Hospital, Melbourne, Australia
| | - Pamela Kearns
- Cancer Research UK Clinical Trials Unit, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom
| | | | - Kathy Pritchard-Jones
- UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
| | | | | | | |
Collapse
|
2
|
Mauz-Körholz C, Metzger ML, Kelly KM, Schwartz CL, Castellanos ME, Dieckmann K, Kluge R, Körholz D. Pediatric Hodgkin Lymphoma. J Clin Oncol 2015; 33:2975-85. [PMID: 26304892 DOI: 10.1200/jco.2014.59.4853] [Citation(s) in RCA: 120] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Hodgkin lymphoma (HL) is one of the most curable pediatric and adult cancers, with long-term survival rates now exceeding 90% after treatment with chemotherapy alone or combined with radiotherapy (RT). Of note, global collaboration in clinical trials within cooperative pediatric HL study groups has resulted in continued progress; however, survivors of pediatric HL are at high risk of potentially life-limiting second cancers and treatment-associated cardiovascular disease. Over the last three decades, all major pediatric and several adult HL study groups have followed the paradigm of response-based treatment adaptation and toxicity sparing through the reduction or elimination of RT and tailoring of chemotherapy. High treatment efficacy is achieved using dose-dense chemotherapy. Refinement and reduction of RT have been implemented on the basis of results from collaborative group studies, such that radiation has been completely eliminated for certain subgroups of patients. Because pediatric staging and response criteria are not uniform, comparing the results of trial series among different pediatric and adult study groups remains difficult; thus, initiatives to harmonize criteria are desperately needed. A dynamic harmonization process is of utmost importance to standardize therapeutic risk stratification and response definitions as well as improve the care of children with HL in resource-restricted environments.
Collapse
Affiliation(s)
- Christine Mauz-Körholz
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany.
| | - Monika L Metzger
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Kara M Kelly
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Cindy L Schwartz
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Mauricio E Castellanos
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Karin Dieckmann
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Regine Kluge
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| | - Dieter Körholz
- Christine Mauz-Körholz and Dieter Körholz, Martin-Luther-University Medical Center, Halle, Germany; Monika L. Metzger, St Jude Children's Research Hospital, Memphis, TN; Kara M. Kelly, Columbia University Medical Center, New York, NY; Cindy L. Schwartz, MD Anderson Cancer Center, Houston, TX; Mauricio E. Castellanos, Unidad Nacional Oncologia Pediatrica, Guatemala City, Guatemala; Karin Dieckmann, Medical University of Vienna, Vienna, Austria; and Regine Kluge, University of Leipzig, Leipzig, Germany
| |
Collapse
|